OK-101(OK-101) - 药物靶点：Chemerin receptors_在研适应症： …
2023年5月1日 · About OK-101OK-101 is a lipid conjugated chemerin peptide agonist of the ChemR23 G-protein coupled receptor which is typically found on immune cells of the eye …
Tides 速递 | OKYO Pharma完成治疗干眼症的OK-101的2期临床试 …
ok-101是利用膜锚定肽(map)技术开发的一种治疗 干眼病 的新型长效候选药物。在干眼病和角膜神经性疼痛的小鼠模型中，ok-101分别显示出抗炎和减轻疼痛的活性，并且通过药物分子中含有 …
OKYO Pharma Receives FDA Approval of IND for OK-101 in …
2024年2月9日 · OK-101 is the first IND clearance granted by FDA for a drug to begin clinical studies specifically to treat patients suffering with neuropathic corneal pain (NCP), a major …
Tides 速递 | OKYO宣布OK-101首次人体试验结果 - 知乎
OK-101是 ChemR23g蛋白偶联受体 的 脂质偶联趋化素肽激动剂，通常存在于眼部负责炎症反应的免疫细胞上。 OK-101是利用膜锚定肽 (MAP)技术开发的一种治疗干眼病的新型长效候选药物 …
快讯 | OKYO干眼症治疗肽OK-101 Ⅱ期临床IND申请在即 - 知乎
OK-101是一种使用新型膜锚定肽 (MAP) 技术开发的长效酯化Chemerin肽类似物，由一个含10个氨基酸的肽序列（衍生自Chemerin）、一个接头成分和一个锚定脂质结构域组成。
First patient dosed in clinical trial to treat neuropathic corneal pain
2024年10月23日 · According to OKYO Pharma, OK-101 is the first drug candidate to enroll patients specifically diagnosed with neuropathic corneal pain in a clinical trial. The Phase 2 …
Home - OKYO Pharma
Urcosimod (formerly called OK-101) Drug Candidate Urcosimod is a novel class of chemerin (ChemR23 or CMKLR1) receptor agonist that produces an anti-inflammatory and reduction in …
眼部疾病药物开发商OKYO Pharma宣布OK-101（0.05%）眼药水 …
2024年3月22日 · OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief …
OKYO Pharma Announces OK-101 Successfully Achieved …
2024年1月8日 · OK-101 has been shown to produce anti-inflammatory and pain-reducing activities in mouse models of dry eye disease and corneal neuropathic pain (NCP), …
OKYO Pharma announces plans for Phase 2 clinical trial of OK-101 …
2024年7月11日 · OKYO Pharma has announced its plan to advance OK-101 into a phase 2 clinical trial of neuropathic corneal pain, expected to begin in Q3 of 2024. The announcement …